Results 21 to 30 of about 4,708 (131)

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

Viruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini, Diego Cecchini, Sofía Diana Menendez, Liliana Calanni, Rosana Cuini, Elena Obieta, María M. Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti, on behalf of the COVIDARE Study Team   +13 more
doaj   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

Journal of Renal and Hepatic Disorders, 2018
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections.
Nicole Marie Lioufas, Alan Street, Paul Champion de Crespigny, Stephen G Holt   +3 more
doaj   +1 more source

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP, Nicole Bradley PharmD, BCPS, BCIDP, Yuman Lee PharmD, BCIDP, AAHIVP   +2 more
doaj   +1 more source

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study

AIDS Research and Therapy, 2021
Background Antiretrovirals, including tenofovir, can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate it. Patients with HIV infection are administered antiretroviral drugs over a long term; thus, managing consequent ...
Mahoko Ikeda, Yoshitaka Wakabayashi, Koh Okamoto, Shintaro Yanagimoto, Shu Okugawa, Kyoji Moriya   +5 more
doaj   +1 more source

Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma

Alimentary Pharmacology &Therapeutics, EarlyView.
In 902 patients with HBV‐related HCC undergoing curative resection, antiviral regimens (ETV, TDF, TAF) showed comparable recurrence‐free survival. However, TDF was independently associated with improved overall survival compared with ETV. ABSTRACT Background & Aims The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and ...
Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hye Won Lee   +10 more
wiley   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Journal of Clinical Virology Plus
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity ...
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione   +6 more
doaj   +1 more source

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate

Pharmaceutical Fronts, 2023
(R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 ...
Man Li, Ting Zhou, Qing-Wen Zhang
doaj   +1 more source

UltRaSoUnd‐guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study

HIV Medicine, EarlyView.
Abstract Objectives We aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction‐associated steatotic liver disease (MASLD) in a cohort of middle‐aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis.
Mariacristina Poliseno, Davide Capruzzi, Antonio Cianciaruso, Nicola Colavito, Felicia Dalitto, Vincenzo Giliberti, Vittoria Lobalsamo, Giuliana Metrangolo, Marica Noviello, Alessandra Vigna, Maurizio Zarcone, Francesco Di Gennaro, Vincenzo Ostilio Palmieri, Annalisa Saracino   +13 more
wiley   +1 more source

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis

Journal of the International AIDS Society
Introduction Among many antiretroviral drugs, tenofovir alafenamide is used extensively in combination regimens of tenofovir/emtricitabine or tenofovir/emtricitabine/bictegravir.
Jeong‐Ju Yoo, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Min Jae Kim   +4 more
doaj   +1 more source